# PT-141 Effects, Benefits & Safety: What the Research Shows > PT-141 (bremelanotide) effects, benefits, and safety: what the trials measured, what users report (anecdotal), and the cited cautions — blood pressure, nausea, hyperpigmentation. What the controlled trials actually measured, kept separate from what people report, kept separate again from the safety cautions grounded in the label and mechanism. ## The short version Here is the honest shape of PT-141 effects. In women diagnosed with HSDD, the approved peptide produced a real but small increase in sexual desire and a small drop in the distress tied to low desire, measured on validated questionnaires over 24 weeks [3]. "Small but real" is the fair summary — and independent reviewers have argued the benefit, while statistically significant, may be modest in everyday terms [11]. The most common cost is nausea: about 40% of women reported it over long-term use, and it was a leading reason people stopped [4]. Flushing and headache were next [4]. Two safety items matter more than their frequency suggests: a transient rise in blood pressure, which is why the label warns against use with uncontrolled high blood pressure or heart disease [7], and skin or gum darkening (hyperpigmentation) with repeated frequent dosing [7]. Below, the cited findings, then a clearly-labeled note on what users report, then the cautions. ## PT-141 benefits What the studies measured. In two identical Phase 3 trials (RECONNECT, 1,267 premenopausal women with HSDD), bremelanotide 1.75 mg given subcutaneously as needed improved sexual desire on the Female Sexual Function Index desire score by an integrated +0.35 (P<.001) and reduced desire-related distress on a validated distress-scale item by −0.33 (P<.001) versus placebo [3]. Both coprimary endpoints were met in both trials. Those improvements held up. In the 52-week open-label extension (684 women), desire gains were sustained with no new safety signals [4]. A 2026 systematic review and meta-analysis pooled the trial data and found bremelanotide improved total Female Sexual Function Index scores plus the desire and arousal subscales [12]. The mechanism behind the benefit is central, not vascular: in a placebo-controlled brain-imaging study of 31 women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and changed how the brain processed erotic cues [5]. ## PT-141 reviews **These are effects described in research-use and patient communities — anecdotal, not clinical evidence, and not verified by controlled trials.** They are summarized here in plain terms, without doses, so a reader has honest context alongside the cited data above. On the benefit side, the most frequently reported theme mirrors the trial endpoint: a rise in sexual desire or interest that some describe as a mental or emotional shift rather than a purely physical one, consistent with the central mechanism. Onset is commonly reported as delayed by some hours rather than immediate. On the adverse side, nausea dominates the reports — exactly as the trials would predict [4] — and is the effect most often blamed for discontinuation. Flushing, headache, and temporary tiredness are also commonly described. Less frequently, people report the skin-darkening effect the label attributes to the melanocortin pathway [7]. None of these reports is a substitute for the controlled data above, and none should be read as a finding. ## PT-141 side effects Safety & cautions. These are drawn from the prescribing information and the trial record, with the mechanism noted where a caution is theoretical rather than demonstrated. **Nausea, flushing, headache.** The most common treatment-emergent effects in long-term use were nausea (40.4%), flushing (20.6%), and headache (12.0%); nausea was the principal tolerability problem and a driver of discontinuation [4]. This is a documented clinical finding, not a theoretical one. **Blood pressure.** Bremelanotide causes transient increases in blood pressure after dosing. The label therefore states it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease [7]. This caution is grounded in measured ambulatory blood-pressure data, not speculation. **Hyperpigmentation.** Darkening of the face, gums, and breasts has been reported with repeated frequent dosing and is attributed to activation of the MC1R melanocortin receptor in the skin [7]. The risk rises with more-frequent dosing than the approved as-needed schedule. **Appetite circuits (theoretical for desire use).** Because MC4R also sits in appetite circuits, caloric-intake and body-weight effects appeared in high-frequency Phase 1 dosing — a relevant pharmacological consideration, not an approved use and not expected at the as-needed schedule [7]. **Research-chemical status.** PT-141 sold as a "research chemical" sits outside the pharmaceutical approval framework, with no regulatory oversight of identity, purity, or concentration [7]. None of the trial safety data was generated with such material, so it cannot be assumed to apply to it. --- A regulatory-careful reading room on PT-141 (bremelanotide): the single 2019 approval for premenopausal HSDD held distinct from every off-label and research-chemical use, each figure logged to the trials or the FDA label — a reading desk organized around the prescription record, never a place that writes, fills, or fulfils one.